MISONIX, INC. (NASDAQ:MSON) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition
On August 22, 2017, Misonix, Inc. (the “Company”) issued a press release announcing financial results of its fourth fiscal quarter ended June 30, 2017. The press release is furnished and attached hereto as Exhibit 99.1. The information in this Item and the aforementioned press release shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, and is not incorporated by reference into any filing of the Company, whether made before or after the date of this report, regardless of any general incorporation language in the filing.
Item 9.01. Financial Statements and Exhibits
|Exhibit No.||Description of Exhibit|
|99.1||Press Release dated August 22, 2017|
MISONIX INC ExhibitEX-99.1 2 s107278_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Misonix Reports Fiscal Year 2017 Financial Results For Immediate Release Corporate Contact Investor Contact Joe Dwyer Joe Diaz Misonix,…To view the full exhibit click
About MISONIX, INC. (NASDAQ:MSON)
MISONIX, INC. (Misonix) is a surgical device company. The Company designs, manufactures and markets therapeutic ultrasonic products across the world for spine surgery, skull-based surgery, neurosurgery, wound and burn debridement, cosmetic surgery, laparoscopic surgery and other surgical applications. The Company’s products include BoneScalpel, BoneScalpel MIS System, SonicOne O.R. System and SonaStar. BoneScalpel is an ultrasonic cutting system with applications in orthopedic and reconstructive surgery, as well as neurosurgery. BoneScalpel MIS System offers deep cuts through osseous structures with minimal blood loss. Misonix SonicOne O.R. System is an ultrasonic surgical debridement system that allows surgeons to address the challenges chronic wounds present to them, the patient, and the health-care system. SonaStar is used for neurosurgical procedures, such as skull/non-skull base tumor resections, transnasal procedures and acoustic mengiomas.